BioMarin Pharmaceutical Inc. (BMRN)
| Market Cap | 10.30B |
| Revenue (ttm) | 3.22B |
| Net Income (ttm) | 348.90M |
| Shares Out | 193.27M |
| EPS (ttm) | 1.80 |
| PE Ratio | 29.53 |
| Forward PE | 9.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,182,151 |
| Open | 54.13 |
| Previous Close | 53.81 |
| Day's Range | 53.19 - 54.13 |
| 52-Week Range | 50.76 - 66.28 |
| Beta | 0.29 |
| Analysts | Buy |
| Price Target | 88.22 (+65.52%) |
| Earnings Date | May 4, 2026 |
About BMRN
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price target is $88.22, which is an increase of 65.52% from the latest price.
News
BioMarin Completes Acquisition of Amicus Therapeutics
Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio BioMarin Expects to ...
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conf...
BioMarin Announces Board Leadership Transition
Ian T. Clark elected Chair of the Board; Richard A. Meier to retire SAN RAFAEL, Calif.
Top 3 Health Care Stocks That Are Set To Fly In March
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
BioMarin stops mid-stage trials of bone disorder treatment
BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker said on Monday, se...
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, buildin...
BioMarin Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference
Revenue grew 13% in 2025, with strong performance from Voxzogo and enzyme therapies. Key 2026 catalysts include major phase III readouts, the Amicus acquisition, and new product launches. Commercial focus remains on expanding access, managing competition, and leveraging operational synergies.
BioMarin Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026
Revenue grew 13% in 2025, with high single-digit growth expected in 2026. Key pipeline milestones include phase III data for VOXZOGO in hypochondroplasia and BMN 401 for ENPP1 deficiency. The Amicus acquisition is set to expand the portfolio and drive accretion by 2027.
BioMarin Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference
A strategic refresh has driven recent acquisitions and a focus on pipeline expansion, with 2026 guidance reflecting competitive and revenue headwinds but projecting solid growth in enzyme therapies and skeletal conditions. Key products like Voxzogo and Palynziq are positioned for continued growth, while new clinical milestones and the Amicus acquisition are expected to drive long-term value.
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the only enzyme substitution therapy app...
BioMarin to Participate in Four Upcoming Investor Conferences in March
TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 Leerink 2026 Global Healthcare Conference on Monday, March 9, 2026 Jefferies 2026 Biotech on the Beach Summit on Tuesday, March ...
BioMarin Pharmaceutical Earnings Call Transcript: Q4 2025
Delivered 13% revenue growth in 2025, driven by enzyme therapies and Voxzogo, with strong profitability and cash flow. 2026 guidance anticipates continued high single-digit growth, major pipeline milestones, and integration of Amicus assets to accelerate long-term expansion.
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO® Fourth Quarter 2025 Total Revenues Increased 17% Y/Y ...
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
SAN RAFAEL, Calif., Feb. 17, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a confe...
BioMarin Announces Closing of Private Offering of Senior Notes
SAN RAFAEL, Calif., Feb. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500% se...
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% se...
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
SAN RAFAEL, Calif., Jan. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850 millio...
BioMarin Appoints Arpit Davé Chief Digital and Information Officer
Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry S...
BioMarin Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference
A major transformation has driven strong revenue growth, cost optimization, and a robust pipeline, highlighted by the Amicus acquisition and expansion of Voxzogo. Multiple R&D catalysts and strategic IP defenses position the company for sustained double-digit growth into the 2030s.
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at th...
Veeva and BioMarin Form Long-Term Strategic Partnership
Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovative therapies PLEASANTON, Calif., and SAN RAFAEL, Calif.
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicu...
What's Going On With BioMarin Stock On Tuesday?
On Friday, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) agreed to acquire Amicus Therapeutics, Inc. (NASDAQ: FOLD) for a total equity value of about $4.8 billion.
BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.
It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.
BioMarin Pharmaceutical Transcript: M&A Announcement
The acquisition adds two high-growth rare disease therapies, immediately accelerating revenue and diversifying the portfolio. The $4.8B all-cash deal is expected to be accretive by 2027, with significant expansion and synergy opportunities, and positions the company for long-term growth.